Successful primary endpoint results of MINIject in the European clinical trial STAR-II have been published in the peer-reviewed Journal of Glaucoma. The data confirm that MINIject met the study primary endpoints with over 75 percent of patients reaching prospectively defined success.
In the trial, mean intraocular pressure (IOP) was reduced by 40 percent to 14.7 mm HG six months after implantation, from 24.6 mm Hg at trial start. In addition, over 55 percent of patients became and remained medication free for at least six months. Minimal change in corneal endothelial cell density was observed.
The data now published on the outstanding efficacy of MINIject from the initial months of the STAR-II trial are consistent with those from other ongoing MINIject trials.
, explained iSTAR Medical CEO, Michel Vanbrabant.
MINIject offers better, safer and enduring care for patients with glaucoma.
, he added.
The Journal of Glaucoma is the official publication of the World Glaucoma Association. The final 24-month data from the MINIject STAR-I trial and the initial six-month data from the STAR-II trial conducted in European centres will be presented at the upcoming annual meeting of the European Society of Cataract and Refractive Surgery (ESCRS) on 2-4 October.
